A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission-Reference-Cited by-同舟云学术

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Published:2016-04-22 Issue:4 Volume:8 Page:46
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

O’Cearbhaill Roisin,Ragupathi Govind^ORCID,Zhu Jianglong,Wan Qian,Mironov Svetlana,Yang Guangbin,Spassova Maria,Iasonos Alexia,Kravetz Sara,Ouerfelli Ouathek,Spriggs David,Danishefsky Samuel,Sabbatini Paul

Funder

National Cancer Institute

National Institutes of Health

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

http://www.mdpi.com/2072-6694/8/4/46/pdf

Reference17 articles.

1. Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

2. Advanced epithelial ovarian cancer: From standard chemotherapy to promising molecular pathway targets—where are we now?;Syrios;Anticancer Res.,2014

3. Consolidation for Ovarian Cancer in Remission

4. Selection of tumor antigens as targets for immune attack using immunohistochemistry: Protein antigens;Zhang;Clin. Cancer Res.,1998

5. Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine;Vaccines;2024-05-28

2. Tumor-Associated Carbohydrate Antigens (TACA) as Novel Targets for Anticancer Therapy;Handbook of Cancer and Immunology;2024

3. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors;Cancers;2023-07-08

4. Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines;Biotechnology Advances;2023-07

5. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission;Cancers;2023-02-25